Lydia Woelflingseder

Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding, Lydia Woelflingseder, Anke Baum et al. · Cancer Discovery · 2024 · 54 citations · Full text

Medicine, Oncology, Pharmacology +15

Identification of a novel human deoxynivalenol metabolite enhancing proliferation of intestinal and urinary bladder cells

Benedikt Warth, Giorgia Del Favero, Gerlinde Wiesenberger et al. · Scientific Reports · 2016 · 51 citations · Full text

Pharmacy, Food Science, Toxicology +17

The Fusarium metabolite culmorin suppresses the in vitro glucuronidation of deoxynivalenol

Lydia Woelflingseder, Benedikt Warth, Immina Vierheilig et al. · Archives of Toxicology · 2019 · 42 citations · Full text

Life Sciences, Biochemistry, Toxicology +13

The Influence of Processing Parameters on the Mitigation of Deoxynivalenol during Industrial Baking

David Stadler, Francesca Lambertini, Lydia Woelflingseder et al. · Toxins · 2019 · 37 citations · Full text

Pharmacy, Food Science, Toxicology +17

The secondary Fusarium metabolite aurofusarin induces oxidative stress, cytotoxicity and genotoxicity in human colon cells

Katharina Jarolim, Konstantin Wolters, Lydia Woelflingseder et al. · Toxicology Letters · 2017 · 35 citations

Life Sciences, Microbiology, Toxicology +12